Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Clinical trial NCT03852823 · UNKNOWN

Trial details

NCT number: NCT03852823
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumours Cervical Cancer Malignant Mesothelioma Lymphoma Non-Small-Cell Lung Cancer

Start date: 2019-05-23
Primary completion: 2022-09-01
Enrollment: 192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.